BridgeMD
The GranStone Trial
EU CTIS ID: 2026-525608-85-00
What this study is testing
The main objective is to determine whether treatment with empagliflozin or losartan can reduce the risk of kidney stones and disease progression in patients with paraffin induced granulomas.
- Phase II and Phase III (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Signed informed consent by participant
- Male
- 18-70 years
- Paraffin granuloma disease with hypercalcemia, hypoparathyroidism, hypercalciuria or a history of nephrolithiasis
You likely can't join if
- eGFR < 20 ml/min
- Cancer (past or present, except basal cell skin cancer or squamous cell skin cancer), which in the investigator’s opinion could interfere with the results of the trial
- Type 1 DM
- Known autosomal dominant or autosomal recessive polycystic kidney disease, lupus nephritis or ANCA-associated vasculitis
- History of organ transplantation
- Receiving therapy with an SGLT2 inhibitor or ATII antagonist within 8 weeks prior to enrolment or previous intolerance of an SGLT2 inhibitor or ATII antagonist.
See the full eligibility criteria
- Signed informed consent by participant
- Male
- 18-70 years
- Paraffin granuloma disease with hypercalcemia, hypoparathyroidism, hypercalciuria or a history of nephrolithiasis
- eGFR < 20 ml/min
- Cancer (past or present, except basal cell skin cancer or squamous cell skin cancer), which in the investigator’s opinion could interfere with the results of the trial
- Type 1 DM
- Known autosomal dominant or autosomal recessive polycystic kidney disease, lupus nephritis or ANCA-associated vasculitis
- History of organ transplantation
- Receiving therapy with an SGLT2 inhibitor or ATII antagonist within 8 weeks prior to enrolment or previous intolerance of an SGLT2 inhibitor or ATII antagonist.
- Known history of angioedema
- Mental incapacity, language barriers or unwillingness to comply with the requirements of the protocol, which may preclude adequate understanding or co-operation during the trial, as judged by the investigator
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling male, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.